Keymed Biosciences' IL-4Rα Antibody Stapokibart Shows Promising Results in Phase III Trial for Seasonal Allergic Rhinitis

Keymed Biosciences Inc. announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its ...

April 07, 2025 | Monday | News
ABL Bio and GSK Forge Licensing Agreement to Develop Innovative Neurodegenerative Disease Treatments Using BBB Shuttle Platform

ABL Bio Inc. a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a wor...

April 07, 2025 | Monday | News
AVITA Medical Launches Cohealyx™ in the U.S., Expanding Portfolio for Transformative Acute Wound Care

AVITA Medical, Inc., a leading therapeutic acute wound care company delivering transformative solutions, announced the U.S. commercial launch of Cohealyx&t...

April 07, 2025 | Monday | News
Novartis Receives FDA Accelerated Approval for Vanrafia® in Treatment of Primary IgA Nephropathy

Novartis announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia® (atrasentan), a potent and selective e...

April 03, 2025 | Thursday | News
Genentech Reports Phase III MUSETTE Trial Results for Ocrevus® Showing No Additional Benefit from Higher Dose in Relapsing MS

Genentech, a member of the Roche Group, announced  that the Phase III MUSETTE trial comparing a high dose of Ocrevus® (ocrelizumab) intraveno...

April 03, 2025 | Thursday | News
Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from China’s NMPA for Melanoma Treatment

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment o...

April 02, 2025 | Wednesday | News
Yingli Pharma Receives FDA Clearance to Launch Phase 3 Trial for Linperlisib in Relapsed/Refractory PTCL

Shanghai Yingli Pharmaceutical Co., Ltd., a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic, and immune dis...

April 02, 2025 | Wednesday | News
Castle Biosciences to Present Key Data on DecisionDx-Melanoma at EADO 2025 Congress

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, will share data via two poster presentations at the ...

April 02, 2025 | Wednesday | News
Inventiva Completes Patient Enrollment in Phase 3 NATiV3 Trial for MASH Treatment

Inventiva ("Inventiva" or the "Company"), a clinical-focused biopharmaceutical company focused on the development of orally administered small molecule dru...

April 02, 2025 | Wednesday | News
Franco Cavaleri's Groundbreaking Study Challenges Amyloid β-Peptides' Role in Alzheimer's Disease

Franco Cavaleri, B.Sc., Ph.D.c, a distinguished biomedical research scientist and CEO of Biologic Pharmamedical Research and Manufacturing, has publis...

April 01, 2025 | Tuesday | News
Hoth Therapeutics Receives USPTO Filing Receipt for New Patent on HT-001 Formulation

 Hoth Therapeutics, Inc. , a patient-focused clinical-stage biopharmaceutical company, announced that it has received an official Filing Rec...

April 01, 2025 | Tuesday | News
Merck Exercises Global Commercialization Option for Pimicotinib, Marking a Milestone in Partnership with Abbisko Therapeutics

Abbisko Therapeutics Co., Ltd. announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fe...

April 01, 2025 | Tuesday | News
Alnylam Presents New Data from HELIOS-B Trial at ACC.25, Highlighting Vutrisiran’s Impact on ATTR-CM Treatment

Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced moderated poster presentations of new data from the landmark HELIOS-B...

March 31, 2025 | Monday | News
Regeneron and Sanofi Receive Approval for Dupixent® in Japan to Treat Chronic Obstructive Pulmonary Disease (COPD)

TARRYTOWN -- Regeneron Pharmaceuticals, and Sanofi announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan ...

March 31, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close